Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Nov;36(11):2055-2063.
doi: 10.1111/jdv.18166. Epub 2022 May 21.

A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece - the 'APRAISAL' study

D Ioannides  1 , N Antonakopoulos  2 , V Chasapi  3 , C Oikonomou  4 , E Tampouratzi  5 , E Lazaridou  6 , D Rigopoulos  7 , O Neofotistou  8 , A Drosos  9 , G Anastasiadis  10 , E Rovithi  11 , C Kalinou  12 , E Papadavid  13 , P Aronis  14 , M Papageorgiou  15 , A Protopapa  16 , I Bassukas  17 , I Lefaki  18 , E Zafiriou  19 , K Krasagakis  20 , E Pokas  21 , Z Anagnostopoulos  22 , A Kekki  2 , M Papakonstantis  23
Affiliations
Observational Study

A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece - the 'APRAISAL' study

D Ioannides et al. J Eur Acad Dermatol Venereol. 2022 Nov.

Abstract

Background: Real-world data in patients with moderate psoriasis treated with apremilast is limited.

Objectives: To evaluate the effectiveness and safety of apremilast in bio-naïve patients with moderate psoriasis in real-world clinical settings.

Methods: This was a 52-week multicenter, observational, prospective study of adult outpatients with moderate psoriasis {[10% < body surface area < 20% or 10 < psoriasis area severity index (PASI) < 20] and 10 < dermatology quality of life index (DLQI) < 20} initiated on apremilast ≤7 days before enrollment. Missing data were imputed using the last observation carried forward method.

Results: A total of 287 eligible patients (median age: 54.2 years; median psoriasis duration: 9.8 years) were consecutively enrolled. At baseline, the median DLQI and PASI scores were 12.0 and 11.8, respectively. The 52-week DLQI ≤ 5 and PASI75 response rates were 68.3% and 61.0%. At 52 weeks, 70.8% and 72.7% of the patients shifted from moderate/severe/very severe to clear/minimal scalp and palmoplantar psoriasis involvement, respectively; the pruritus severity state improved in 67.2%. The 52-week Kaplan-Meier estimated drug continuation rate was 85.3%. The adverse drug reaction rate was 19.9%.

Conclusions: Apremilast is a safe and effective treatment for bio-naïve patients with moderate psoriasis and specific psoriasis manifestations.

PubMed Disclaimer

Comment in

References

    1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
    1. Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Solé M et al. Epidemiology of psoriasis. A Population-Based Study Actas Dermosifiliogr 2019; 110: 385-392.
    1. Badri T, Kumar P, Oakley AM. Plaque psoriasis. StatPearls. StatPearls Publishing, Treasure Island (FL), 2020.
    1. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One 2012; 7: e52935.
    1. Armstrong A, Jarvis S, Boehncke WH et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol 2018; 32: 2200-2207.

Publication types

Grants and funding

LinkOut - more resources